Drug firm Cipla, on Tuesday, posted a 58.2 per cent rise in its net profit at Rs.400.76 crore for the first quarter ended June 30, 2012 against Rs.253.34 crore in the same period of the previous fiscal. Total income from operations increased by 23.6 per cent to Rs.2,012.44 crore from Rs.1,628.29 crore.
The operating margins grew by 47.1 per cent to Rs.563.24 crore from Rs.382.93 crore.
Domestic revenues increased by 30.4 per cent to Rs.969.67 crore from Rs.743.64 crore largely on account of growth in anti-asthma and anti-biotics therapy segments. Exports of formulations rose by 23 per cent to Rs.810.11 crore from Rs.658.86 crore. Exports of APIs have declined by 1.7 per cent to Rs.168.46 crore from Rs.171.31 crore. Total exports were higher by 17.9 per cent at Rs.978.57 crore against Rs.830.17 crore primarily due to growth in anti-depressants and anti-cancer segments, a company release said.
